For research use only. Not for therapeutic Use.
DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6. DCLX069 has anticancer effects[1].
DCLX069 (12.5-100 µM) effectively blocks cell proliferation in breast cancer, liver cancer and acute myeloid leukemia cell lines (MCF7, HepG2, and THP1 cells) in a concentration-dependent manner[1].
| Catalog Number | I012686 |
| CAS Number | 792946-69-1 |
| Synonyms | ethyl 3-amino-4-(4-benzylpiperazin-1-yl)benzoate |
| Molecular Formula | C20H25N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H25N3O2/c1-2-25-20(24)17-8-9-19(18(21)14-17)23-12-10-22(11-13-23)15-16-6-4-3-5-7-16/h3-9,14H,2,10-13,15,21H2,1H3 |
| InChIKey | RITRCMIWRZBDID-UHFFFAOYSA-N |
| SMILES | CCOC(=O)C1=CC(=C(C=C1)N2CCN(CC2)CC3=CC=CC=C3)N |
| Reference | [1]. Yiqian Xie, et al. Virtual screening and biological evaluation of novel small molecular inhibitors against protein arginine methyltransferase 1 (PRMT1). Org Biomol Chem. 2014 Dec 21;12(47):9665-73. |
